Hemodialysis Complication

Hemodialysis

Saint-Georges Hospital

Twice Against Thrice-weekly Hemodialysis

Twice-Against Thrice-weekly Hemodialysis: the TATH Trial

Rate of supplementary hemodialysis sessions for pulmonary oedema or hyperkalemia

Rate of uncontrolled hypertension, Uncontrolled hypertension is defined as a pre-dialysis BP > 160/90 in more than 2/3 of the sessions.

Mabel Aoun

Dr Mabel Aoun. Head of the Department of Nephrology, Saint-Georges Hospital Ajaltoun

Saint-Joseph University

The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.

Renal Failure

Spironolactone

Hospital of the Medical School of Botucatu

Effects of Spironolactone in Dialysis

Assessment of the Effects of the Combination of Spironolactone to Conventional Pharmacotherapy in Dialysis Patients

The reduction of left ventricular hypertrophy will be measured by echocardiography, blood pressure monitoring residential and pulse wave velocity.

Measurement of serum potassium and other routine laboratory parameters pertaining to the hemodialysis unit of the Hospital of the Medical School of Botucatu - UNESP.

Greicy Mara Mengue Feniman De Stefano

UPECLIN HC FM Botucatu Unesp

Titration phase with sevelamer (Renagel) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.
Increase of sevelamer dose up to 12 tablets, as follows:
0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week).

Titration phase with nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks of treatment, with stable dose of calcic carbonate.
Increase of nicotinamide dose up to 4 tablets, as follows:
0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week).

Chronic Renal Failure

Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;
Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:
0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week).

nicotinamide

Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.
Increase of sevelamer dose up to 12 tablets, as follows:
0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week).

sevelamer

After 6 months of treatment, patient screening on PTH level:
For patients with PTH > 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH < 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be < 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia < 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.
A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l.

cinacalcet

Centre Hospitalier Général

Centre Hospitalier

ALURAD

Centre Hospitalier Universitaire

Association Régionale Promotion Dialyse à domicile (ARPDD)

Association pour le Développement de l'Hémodialyse

Polyclinique de la Louvière

CHRU

Hôpital Victor Provo

Clinique Saint Côme

Clinique du Bois Bernard

Centre Hospital-Universitaire d'Amiens

Clinique de l'Europe

Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients

Comparison of Nicotinamide and Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients

Centre Hospitalier Universitaire, Amiens

Placebo

Potassium Citrate

Total

Sex: Female, Male

Region of Enrollment

25-OH Vitamin D

One measure of bone turnover was urinary-NTX as a second void morning urine.

Urinary-N-telopeptide

BMD was performed at lumbar spine, total hip and femoral neck using dual-energy X-ray Absorptiometry (DXA) Hologic; Bedford, Massachusetts.

Number of Participants With Stable Bone Mineral Density (BMD) Over 12 Months at All Sites.

One measure of bone turnover was P1NP as a morning lab draw.

P1NP (Amino-terminal Propeptide of Type I Procollagen)

Potassium Citrate 20 meq twice daily
potassium citrate: 20 meq by mouth in capsule form twice daily

Placebo
Placebo 20 meq by mouth in capsule form twice daily

Overall Study

Assistant Professor of Medicine

Placebo
potassium citrate: 20 meq by mouth in capsule form twice daily

Bone Diseases, Metabolic

Osteoporosis, Postmenopausal

20 meq by mouth in capsule form twice daily

hyperkalemia/phosphatase

Twice Against Thrice-weekly Hemodialysis

Effects of Spironolactone in Dialysis

Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients

The Effects of Potassium Citrate on Bone Metabolism

Die vollständigste Datenbank für Heilkräuter, die von der Wissenschaft unterstützt wird